SESSION 3
Biology of breast cancer II: Intratumoral heterogeneity and therapeutic implications

Chairs: Jonas Bergh (Sweden), C. Kent Osborne (USA)

Intratumoral heterogeneity and subclonal diversification of early breast cancer

 Lucy R. Yates, UK

Clonal evolution and clonal selection induced by therapy in the adjuvant and neoadjuvant settings

 Charles Perou, USA

Overcoming resistance through genomically informed investigational cancer therapy?

Fabrice André, France

 Clinical utility of genomic biomarkers in the adjuvant setting

 Daniel F. Hayes, USA

Discussion